ADCT ADC Therapeutics SA

CIK 0001771910 36 ready 8-Ks latest October 13, 2026, 6:26 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 36

Latest filing October 13, 2026, 6:26 AM ET

Top materiality 0.95

Event mix other_material ×15 · earnings ×12 · other ×7

Sentiment 7 pos · 4 neg · 25 neu

Latest earnings reported 2026-Q1

Recent 8-K filings for ADCT

Highest-materiality recent filing

ADC Therapeutics announces $86.6M PIPE, Blue Owl loan amendment, HCR royalty amendment, and preliminary Q3 revenue

October 13, 2026, 6:26 AM ET other material materiality 0.95 positive item 1.01 item 2.02 item 3.02 item 9.01

ADC Therapeutics agreed to sell 12,911,347 common shares at $1.4200 and pre-funded warrants for 48,088,653 shares at $1.32400 in an $86.6M private placement expected to close Oct. 22, 2026.
Blue Owl loan amendment prepays $70.0M principal, cuts outstanding term loans to $50.0M, eliminates the minimum liquidity covenant, and sets minimum trailing U.S. ZYNLONTA sales at $65.0M.

Read filing →

October 13, 2026, 6:26 AM ET other material materiality 0.95 positive item 1.01 item 2.02 item 3.02 item 9.01

ADC Therapeutics announces $86.6M PIPE, Blue Owl loan amendment, HCR royalty amendment, and preliminary Q3 revenue

ADC Therapeutics agreed to sell 12,911,347 common shares at $1.4200 and pre-funded warrants for 48,088,653 shares at $1.32400 in an $86.6M private placement expected to close Oct. 22, 2026.
August 13, 2026, 9:14 AM ET earnings materiality 0.80 negative item 2.02 item 7.01 item 9.01

ADC Therapeutics Q2 revenue $18.6M; FDA flags LOTIS-5 benefit-risk concerns

Q2 net product revenue $18.6M vs $18.1M YoY; six-month revenue $38.7M vs $35.5M.
June 24, 2026, 9:00 AM ET other material materiality 0.65 neutral item 7.01 item 8.01 item 9.01

ADC Therapeutics cuts 17% of workforce, expects $10M annual savings; pre-sBLA meeting in Aug 2026

Workforce reduction of ~17% globally, expected to generate ~$10M annualized cost savings.
June 3, 2026, 4:17 PM ET other material materiality 0.80 neutral item 7.01 item 8.01 item 9.01

ADC Therapeutics: LOTIS-5 Phase 3 meets PFS endpoint; sBLA submission planned Q4 2026

PFS HR=0.73 (p=0.008); median PFS 6.1 mo ZYNLONTA+ritux vs 4.7 mo R-GemOx.
March 10, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

ADC Therapeutics posts Q4 revenue $22.3M; net loss narrows; LOTIS-5 topline data expected Q2 2026

Q4 net product revenue $22.3M, full year $73.6M, up from $16.4M and $69.3M respectively in 2024.
February 23, 2026, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 3.02 item 9.01 ◈ Material Agreements

ADC Therapeutics cuts change-of-control payment to HCR from $750M to $150-200M; issues warrants

Under amended HCR agreement, change-of-control payment reduced to $150M before 2028 or $200M after, from $750M previously.
January 8, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 7.01 item 9.01

ADC Therapeutics reports preliminary 2025 revenue of ~$73M; cash runway extended to 2028

Preliminary Q4 2025 ZYNLONTA net product revenue ~$22M; full year 2025 ~$73M vs $69.3M in 2024.
December 5, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01

ADC Therapeutics reports 89.8% ORR and 77.6% CR in LOTIS-7 trial of ZYNLONTA + glofitamab in r/r DLBCL

Best ORR 89.8% (44/49); CR rate 77.6% (38/49) across dose levels.
November 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

ADC Therapeutics Q3 net product revenue $15.8M; net loss narrows to $41M; $60M PIPE strengthens cash

Q3 net product revenue $15.8M (down 12% YoY); nine-month 2025 revenue $51.2M vs $52.9M in 2024.
October 14, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 2.02 item 3.02 item 9.01 ◈ Equity Issuances ×2

ADC Therapeutics raises $60M PIPE; prelim Q3 ZYNLONTA revenue $15.8M, cash $234.7M

PIPE of 11.25M shares at $4.00 and 3.85M pre-funded warrants at $3.90; gross $60M, close expected Oct 27.
September 30, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

ADC Therapeutics updates with strong LOTIS-7 combo data; ZYNLONTA expansion plans detailed

LOTIS-7 (ZYNLONTA+glofitamab) achieved 86.7% CR rate in r/r LBCL; 93.3% ORR in evaluable patients (N=30).
August 12, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

ADC Therapeutics Q2 net loss widens to $56.6M; completes $100M PIPE, cuts workforce 30%

Q2 product revenue $18.1M (+6% YoY); net loss $56.6M ($0.50/share) vs $36.5M loss ($0.38) in Q2 2024.
June 12, 2025, 7:59 PM ET other material materiality 0.85 neutral item 1.01 item 2.05 item 3.02 item 9.01 ◈ Restructurings & Charges

ADC Therapeutics announces $100M private placement and restructuring with 30% workforce cut

$100M private placement: 13.03M shares at $3.53 & 15.73M pre-funded warrants at $3.432; close June 16, 2025.
May 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

ADC Therapeutics Q1 net loss narrows to $38.6M; ZYNLONTA revenue $17.4M, LOTIS-7 shows 95.5% ORR

Q1 product revenue $17.4M vs $17.8M YoY; license revenue $5.6M including $5M Canadian milestone.
March 27, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

ADC Therapeutics reports Q4/FY2024 results: net loss narrows; ZYNLONTA revenue flat; cash runway to H2 2026

Net loss Q4 2024 was $30.7M ($0.29/share) vs $85.0M ($1.03) in Q4 2023; full year net loss $157.8M ($1.62) vs $240.1M ($2.94).
November 7, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

ADC Therapeutics reports Q3 2024 revenue $18.0M; net loss narrows; discontinues ADCT-601

ZYNLONTA net product revenue $18.0M in Q3 2024 vs $14.3M in Q3 2023; year-to-date $52.9M.
August 6, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

ADC Therapeutics Q2 2024: ZYNLONTA $17M (−5% QoQ), net loss $36.5M, cash extended to mid-2026

ZYNLONTA net sales $17.0M in Q2 2024 (−5% QoQ, −11% YoY); commercial profitability achieved.
May 8, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

ADC Therapeutics raises ~$105M in public offering of common shares and pre-funded warrants

Offered 13.4M common shares at $4.90/share and pre-funded warrants for 8.2M shares at $4.812/warrant.
May 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ADC Therapeutics Q1 net loss narrows to $46.6M; ZYNLONTA sales $17.8M; initial MZL data shows 13/15 CR

ZYNLONTA net sales $17.8M in Q1 2024, up 7% QoQ, down 6% YoY; total operating expenses down 25%.
March 13, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

ADC Therapeutics reports Q4'23 ZYNLONTA sales $16.6M, net loss $85M; cash runway into Q4'25

ZYNLONTA net sales $16.6M in Q4'23 (+17% QoQ, -16% YoY); FY'23 $69.1M (-8% YoY).
January 19, 2024, 6:59 PM ET debt materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements

ADC Therapeutics amends loan; adds ZYNLONTA sales covenant, eases out-license repay

New revenue covenant requires ZYNLONTA net sales from $45.5M (trailing 3Q Jun'24) to $94.2M (4Q Jun'29).
January 4, 2024, 6:59 PM ET other material materiality 0.65 neutral item 2.02 item 7.01 item 9.01

ADC Therapeutics reports preliminary ZYNLONTA Q4 net sales ~$16.5M; cash ~$278.5M

Preliminary ZYNLONTA Q4 2023 net sales ~$16.5M, double-digit percentage increase from Q3 2023.

Earnings & guidance

2026-Q1 EPS reported -$0.21 filing →

Materiality & sentiment trend

Max materiality 0.95 · Median 0.65 · Most common event other_material

7 positive 4 negative 25 neutral

source · ADCT on sec.gov